WO2009111177A3 - Compositions and methods comprising genetically enhanced obligate and facultative anaerobic bacteria for oncopathic cancer therapy - Google Patents

Compositions and methods comprising genetically enhanced obligate and facultative anaerobic bacteria for oncopathic cancer therapy Download PDF

Info

Publication number
WO2009111177A3
WO2009111177A3 PCT/US2009/034549 US2009034549W WO2009111177A3 WO 2009111177 A3 WO2009111177 A3 WO 2009111177A3 US 2009034549 W US2009034549 W US 2009034549W WO 2009111177 A3 WO2009111177 A3 WO 2009111177A3
Authority
WO
WIPO (PCT)
Prior art keywords
gene
anaerobic bacteria
genetically enhanced
enhanced anaerobic
oncopathic
Prior art date
Application number
PCT/US2009/034549
Other languages
French (fr)
Other versions
WO2009111177A2 (en
Inventor
Savio L.C. Woo
Zhiyu Li
James Wetmur
Original Assignee
Mount Sinai School Of Medicine Of New York University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mount Sinai School Of Medicine Of New York University filed Critical Mount Sinai School Of Medicine Of New York University
Publication of WO2009111177A2 publication Critical patent/WO2009111177A2/en
Publication of WO2009111177A3 publication Critical patent/WO2009111177A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0065—Oxidoreductases (1.) acting on hydrogen peroxide as acceptor (1.11)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0089—Oxidoreductases (1.) acting on superoxide as acceptor (1.15)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/145—Clostridium

Abstract

Provided are genetically enhanced anaerobic bacteria for the oncopathic therapy of cancers, including pancreatic and otheτ cancers that contain avascular, hypoxic regions. Within certain embodiments, genetically enhanced anaerobic bacteria contain one or more mutation(s). such as, for example, a deletion in one or more oxygen tolerance gene(s) such as a superoxide dismutase (sod), glutathione peroxidase (gpo), rubrerythrin (rbr), and/or an alcohol dehydrogenase family mernbei (ydaD) gene. Within further embodiments, genetically enhanced anaerobic bacteria contain one or more mutation(s), such as, for example, a deletion in one or more toxin gene(s) such as a phospholipase c (plc) gene. Within other embodiments, genetically enhanced anaerobic bacteria further express an inflammation suppressive gene such as, for example, a Staphylococcus aureus Panton-Valentine Leukocidin (PVL) gene and/or a Yersinia enterocolitica virulence factor (LcrV) gene. Genetically enhanced anaerobic bacteria disclosed herein, as exemplified by Clostridium, Bifidobacterium, and Salmonella species, are capable of selectively targeting hypoxic tumors.
PCT/US2009/034549 2008-03-05 2009-02-19 Compositions and methods comprising genetically enhanced obligate and facultative anaerobic bacteria for oncopathic cancer therapy WO2009111177A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3411108P 2008-03-05 2008-03-05
US61/034,111 2008-03-05

Publications (2)

Publication Number Publication Date
WO2009111177A2 WO2009111177A2 (en) 2009-09-11
WO2009111177A3 true WO2009111177A3 (en) 2010-01-07

Family

ID=41056538

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/034549 WO2009111177A2 (en) 2008-03-05 2009-02-19 Compositions and methods comprising genetically enhanced obligate and facultative anaerobic bacteria for oncopathic cancer therapy

Country Status (1)

Country Link
WO (1) WO2009111177A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101285470B1 (en) * 2009-11-20 2013-07-12 고려대학교 산학협력단 Anti-cancer adjuvant comprising Salmonella typhimurium harboring TNF-alpha
CN103025352B (en) 2010-05-05 2017-07-11 纽约大学 Staphylococcus aureus leukocidin and its therapeutic combination and purposes
US9476056B2 (en) 2010-05-12 2016-10-25 Universite De Rennes 1 Recombinant vector for producing and secreting peptide or protein of interest by propionibacteria and applications thereof
FR2960001A1 (en) * 2010-05-12 2011-11-18 Univ Rennes RECOMBINANT VECTOR FOR THE PRODUCTION AND SECRETION OF AMINO ACID SEQUENCES OF INTEREST BY PROPIONIC BACTERIA AND ITS APPLICATIONS
CN103266076B (en) * 2013-06-04 2014-10-29 神舟太空产品高科技成果推广中心集团有限公司 Space-induced efficient bifidobacterium bifidum and application thereof as well as preparation method of capsule preparation of space-induced efficient bifidobacterium bifidum
EP2829274A1 (en) 2013-07-25 2015-01-28 Institut National De La Recherche Agronomique Vectors for producing and secreting substance of interest by bacteria and applications thereof
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
EP3250215A4 (en) * 2015-01-29 2018-08-08 Oxyrase, Inc. Methods for inhibiting tumor growth
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11471497B1 (en) 2019-03-13 2022-10-18 David Gordon Bermudes Copper chelation therapeutics
CN115244069A (en) 2019-12-18 2022-10-25 埃克斯欧姆尼斯生物技术有限公司 Genetically modified clostridium strain and uses thereof
EP4291212A1 (en) 2021-02-15 2023-12-20 LivingMed Biotech S.R.L. Genetically clostridium modifiedstrains expressing recombinant antigens and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030199035A1 (en) * 1997-12-17 2003-10-23 Jose Arnau Metabolically engineered lactic acid bacteria and means for providing same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030199035A1 (en) * 1997-12-17 2003-10-23 Jose Arnau Metabolically engineered lactic acid bacteria and means for providing same

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
"GEMZAR (GEMCITABINE HCI) FOR INJECTION. Pancreatic Cancer", 7 May 2007 (2007-05-07), ELI LILLY AND COMPANY, INDIANAPOLIS, IN 46285, USA,, pages 8 - 10 *
AWAD ET AL.: "Virulence studies on chromosomal alpha-toxin and theta-toxin mutants constructed by allelic exchange provide genetic evidence for the essential role of alpha-toxin in Clostridium perfringens-mediated gas gangrene.", MOLECULAR MICROBIOLOGY, vol. 15, no. 2, January 1995 (1995-01-01), pages 191 - 202 *
BRIOLAT ET AL.: "Identification of the Clostridium perfringens Genes Involved in the Adaptive Response to Oxidative Stress.", JOURNAL OF BACTERIOLOGY, vol. 184, no. 9, May 2002 (2002-05-01), pages 2333 - 2343 *
DE GROOTE ET AL.: "Periplasmic superoxide dismutase protects Salmonella from products of phagocyte NADPH-oxidase and nitric oxide synthase.", PROC. NATL. ACAD. SCI. USA, vol. 94, no. 25, 9 December 1997 (1997-12-09), pages 13997 - 14001 *
ESCUDIER ET AL.: "Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma.", N ENGL J MED, vol. 356, no. 2, 11 January 2007 (2007-01-11), pages 125 - 134 *
GENESTIER ET AL.: "Staphylococcus aureus Panton-Valentine leukocidin directly targets mitochondria and induces Bax-independent apoptosis of human neutrophils.", THE JOURNAL OF CLINICAL INVESTIGATION, vol. 115, no. 11, November 2005 (2005-11-01), pages 3117 - 3127 *
PAWELEK ET AL.: "Bacteria as tumor-targeting vectors.", THE LANCET ONCOLOGY, vol. 4, September 2003 (2003-09-01), pages 548 - 556 *
POYART ET AL.: "Characterization of superoxide dismutase Gram-positive bacteria by polymerase chain degenerate primers.", FEMS MICROBIOLOGY LETTERS, vol. 131, no. 1, 15 August 1995 (1995-08-15), pages 41 - 45 *
RYAN ET AL.: "Use of bacteria in anti-cancer therapies.", BIOESSAYS, vol. 28, no. 1, January 2006 (2006-01-01), pages 84 - 94 *
STASSEN ET AL.: "The Streptococcal Exotoxin Streptolysin O Activates Mast Cells To Produce Tumor Necrosis Factor Alpha by p38 Mitogen-Activated Protein Kinase- and Protein Kinase C- Dependent Pathways.", INFECTION AND IMMUNITY, vol. 71, no. 11, November 2003 (2003-11-01), pages 6171 - 6177 *
THEYS ET AL.: "Tumor-Specific Gene Delivery Using Genetically Engineered Bacteria.", CURRENT GENE THERAPY, vol. 3, no. 3, June 2003 (2003-06-01), pages 207 - 221 *

Also Published As

Publication number Publication date
WO2009111177A2 (en) 2009-09-11

Similar Documents

Publication Publication Date Title
WO2009111177A3 (en) Compositions and methods comprising genetically enhanced obligate and facultative anaerobic bacteria for oncopathic cancer therapy
Tarrant et al. Copper stress in Staphylococcus aureus leads to adaptive changes in central carbon metabolism
Brutinel et al. Shuttling happens: soluble flavin mediators of extracellular electron transfer in Shewanella
Aguirre et al. Battles with iron: manganese in oxidative stress protection
Baureder et al. Contribution of catalase to hydrogen peroxide resistance in Enterococcus faecalis
Pérez et al. Bacterial survival under extreme UV radiation: a comparative proteomics study of Rhodobacter sp., isolated from high altitude wetlands in Chile
Strand et al. Oxidative stress protection and the repair response to hydrogen peroxide in the hyperthermophilic archaeon Pyrococcus furiosus and in related species
Berghoff et al. Anoxygenic photosynthesis and photooxidative stress: a particular challenge for Roseobacter
BRPI1011934A8 (en) COMPOSITION
Lamb et al. Functional role of PilA in iron acquisition in the cyanobacterium Synechocystis sp. PCC 6803
Calderini et al. Comparative proteomics of oxidative stress response of Lactobacillus acidophilus NCFM reveals effects on DNA repair and cysteine de novo synthesis
WO2009099991A3 (en) Treatment of cancer
WO2007137075A3 (en) Use of non-agrobacterium bacterial species for plant transformation
MX2019003005A (en) Lipid containing formulations.
EP2526112A4 (en) Targeted genomic alteration
WO2007028041A3 (en) Loading of cells with antigens by electroporation
MY160389A (en) Higher loading zinc-containing films
Peuser et al. Response of the photosynthetic bacterium Rhodobacter sphaeroides to iron limitation and the role of a Fur orthologue in this response
Grosche et al. Cetia pacifica gen. nov., sp. nov., a chemolithoautotrophic, thermophilic, nitrate-ammonifying bacterium from a deep-sea hydrothermal vent
Imhoff Biology of green sulfur bacteria
Pérez et al. Rhodobacter sp. Rb3, an aerobic anoxygenic phototroph which thrives in the polyextreme ecosystem of the Salar de Huasco, in the Chilean Altiplano
Fourie et al. Transcriptional response of Candida albicans to Pseudomonas aeruginosa in a polymicrobial biofilm
Fieseler et al. Rhamnose-inducible gene expression in Listeria monocytogenes
WO2008092002A3 (en) Compositions and methods for treating and diagnosing pancreatic cancer
Pérez-Rodríguez et al. Phorcysia thermohydrogeniphila gen. nov., sp. nov., a thermophilic, chemolithoautotrophic, nitrate-ammonifying bacterium from a deep-sea hydrothermal vent

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09717518

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09717518

Country of ref document: EP

Kind code of ref document: A2